<p>Athira Pharma, Inc. (ATHA) 发布了其第三季度财报。以下是 Athira Pharma, Inc. 向投资者提供的信息摘要。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
<p>Athira Pharma, Inc. 是一家临床阶段的生物制药公司，专注于开发小分子药物以恢复神经健康并减缓神经退行性变，主要在生物技术领域运营。在其最新的财报中，Athira Pharma 披露了运营费用的显著减少以及净亏损的缩小，与去年相比有了明显改善。该公司报告 2025 年第三季度净亏损为 660 万美元，相较于去年同期的 2870 万美元亏损有了显著改善。这一亏损的减少归因于研发费用的大幅下降，从 1790 万美元降至 280 万美元，以及一般和管理费用的减少。尽管有这些改善，Athira 仍面临挑战，包括需要额外资金来支持其运营和药物候选者的开发。展望未来，Athira Pharma 的管理层仍然专注于推进其产品管线，特别是其主要候选药物 ATH-1105，同时探索战略交易以增强其财务状况。</p>

ATHA

<p>Athira Pharma, Inc. 报告了其第三季度财报，显示净亏损减少至 660 万美元，较去年同期的 2870 万美元有所下降。这一改善得益于运营费用的大幅削减，尤其是研发费用，从 1790 万美元降至 280 万美元。尽管取得了这些进展，公司仍面临挑战，包括需要额外融资。Athira 的管理层专注于推进其药物研发管线，特别是 ATH-1105，同时寻求战略交易以增强其财务稳定性</p>

<p>Athira Pharma, Inc. ( (ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors.</p>
<div class="lb-trans"><p>Athira Pharma, Inc. (ATHA) 发布了其第三季度财报。以下是 Athira Pharma, Inc. 向投资者提供的信息摘要。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的洞察。</li>
</ul>
</div><p>Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, operating primarily in the biotechnology sector. In its latest earnings report, Athira Pharma revealed a significant reduction in operating expenses and a narrower net loss compared to the previous year. The company reported a net loss of $6.6 million for the third quarter of 2025, a notable improvement from the $28.7 million loss in the same period last year. This reduction in losses is attributed to a substantial decrease in research and development expenses, which fell to $2.8 million from $17.9 million, and a decrease in general and administrative expenses. Despite these improvements, Athira continues to face challenges, including the need for additional funding to support its operations and the development of its drug candidates. Looking ahead, Athira Pharma’s management remains focused on advancing its pipeline, particularly its lead candidate ATH-1105, while exploring strategic transactions to bolster its financial position.</p>
<div class="lb-trans"><p>Athira Pharma, Inc. 是一家临床阶段的生物制药公司，专注于开发小分子药物以恢复神经健康并减缓神经退行性变，主要在生物技术领域运营。在其最新的财报中，Athira Pharma 披露了运营费用的显著减少以及净亏损的缩小，与去年相比有了明显改善。该公司报告 2025 年第三季度净亏损为 660 万美元，相较于去年同期的 2870 万美元亏损有了显著改善。这一亏损的减少归因于研发费用的大幅下降，从 1790 万美元降至 280 万美元，以及一般和管理费用的减少。尽管有这些改善，Athira 仍面临挑战，包括需要额外资金来支持其运营和药物候选者的开发。展望未来，Athira Pharma 的管理层仍然专注于推进其产品管线，特别是其主要候选药物 ATH-1105，同时探索战略交易以增强其财务状况。</p>
</div>

Athira Pharma 报告称通过削减成本实现亏损减少